首页> 外文期刊>Trends in pharmacological sciences >Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma
【24h】

Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma

机译:核过氧化物酶体增殖物激活受体γ的配体

获取原文
获取原文并翻译 | 示例
           

摘要

Nuclear receptors are ligand-activated transcription factors, which represent a primary class of drug targets. The nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR eta) is a key player in various biological processes. PPAR eta is widely known as the target protein of the thiazolidinediones for treating type 2 diabetes. Moreover, PPAR eta ligands can induce anti-inflammatory and potentially additional beneficial effects. Recent mechanistic insights of PPAR eta modulation give hope the next generation of efficient PPAR eta-based drugs with fewer side effects can be developed. Furthermore, chemical approaches that make use of synergistic action of combinatorial ligands are promising alternatives for providing tailored medicine. Lessons learned from fine-tuning the action of PPAR eta can provide avenues for efficient molecular intervention via many other nuclear receptors to combat common diseases.
机译:核受体是配体激活的转录因子,代表一类主要的药物靶标。核受体过氧化物酶体增殖物激活受体γ(PPAR eta)是各种生物学过程中的关键角色。 PPAR eta是噻唑烷二酮类用于治疗2型糖尿病的靶蛋白,众所周知。此外,PPAR eta配体可以诱导抗炎和潜在的其他有益作用。最近对PPAR eta调节的机理研究提供了希望,希望能够开发出副作用更少,下一代基于PPAR eta的高效药物。此外,利用组合配体协同作用的化学方法是提供定制药物的有前途的替代方法。从微调PPAR eta的作用中获得的经验教训可以为通过许多其他核受体与常见疾病作斗争的有效分子干预提供途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号